For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

OpenAI CEO Sam Altman and Meta both announced $1 million donations, and Amazon and Apple CEO Tim Cook have also reportedly ...

Metsera's MET-097i shows 11.3% weight loss in Phase 2a trial, beating Wegovy and Zepbound at 3 months, with potential for ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower ...

Investigational once-weekly retatrutide yielded the greatest weight loss of all GLP-1 receptor agonists, up to 22.1% after 48 ...

Ophthalmic diseases specialist Oculis Holding AG announced positive phase II data showing its serum-glucose corticoid ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...